Drug Trial Radar · NCT04986176
HC-1119 Adjuvant Treatment for Hospitalized COVID-19 Patients
Last checked: Nov 20, 2026Latest source record: Feb 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
602
Planned (sponsor's estimate)
Start
Apr 15, 2022
Primary completion
Dec 31, 2022
Study completion Dec 31, 2022
Sponsor
- Lead sponsor
- Applied Biology, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Hinova Pharmaceuticals Inc.
- First posted
- Aug 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the efficacy of HC-1119 as an adjuvant treatment for hospitalized COVID-19 male and female patients.
Conditions
- COVID-19 Respiratory Infection
Interventions
HC-1119Drug
oral
PlaceboDrug
oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- All-cause mortality risk ratio assessed by the proportion of patient deaths in both study arms.Time frame: 28 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.